Antibody-drug conjugate
ulcerative keratitis, neutropenia, fatigue, neuropathy
ULCERATIVE KERATITIS, METASTATIC CERVICAL CANCER, NEUTROPENIA, NEUROPATHY, SOLID TUMORS, PERIPHERAL NEUROPATHIES, CERVICAL CANCER
ADCs have a unique construction that consists of an antibody (to recognize a particular cellular antigen), a cytotoxic molecule (bound to the antibody), and a linker (to hold the two parts together) (Tisotumab Vedotin. TF is highly expressed in solid tumors such as cervical, and it is not or lowly expressed in normal cervical tissues. This supports TF to act as an ideal target for ADCs. The anti-TF ADC Tisotumab Vedotin is the leading ADC in the field of cervical cancer. Tisotumab Vedotin showed good results both as a single agent and in combination with other therapies. In a phase II study of Tisotumab Vedotin as the second-line treatment in patients with recurrent or metastatic cervical cancer, the ORR was 24% (95% CI: 16–33; 7% CR, and 17% PR). The median DoR, PFS, and OS were 8.3 months (95% CI: 4.2–NR), 4.2 months (95% CI: 3.0–4.4), and 12.1 months (95% CI: 9.6–13.9), respectively. Grade 3 or worse TRAEs were reported in 28% of patients, including neutropenia (3%), fatigue (2%), ulcerative keratitis (2%), and peripheral neuropathies (2% each with sensory, motor, sensorimotor, and neuropathy peripheral) (